Thursday November 26 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BTG

BTG is a company focused on the advancement of medical science. We harness innovation, manage the development of therapeutic opportunities and realise commercial value, principally in the fields of Ageing, Neuroscience, Oncology and Drug Repositioning. As experts in sourcing, protecting and developing new products, our scale and experience is helping to transform the commercial potential of medical research programmes from around the globe. Our independence, capacity for investment, and deep pipeline of development projects make us a unique and attractive partner to researchers and the pharmaceutical industry.


Contact Details:
Five Tower Bridge8th Floor
300 Barr Harbor Drive
West Conshohocken
Pennsylvania
19428-2998
United States of America
Tel:1 610 278 1660
Fax:1 610 278 1605
Email:info@btgplc.com
WWW:

www.btgplc.com/




Loading...

Recent Publications by BTG:

The ESCHAR trial: should it change practice?
INTRODUCTION: Most leg ulcers are caused by venous disease, the most...
6th November, 2009
BTG International Limited, Perspect Vasc Surg Endovasc Ther. 2009 Jun;21(2):69-72. Epub 2009 Jul 14.
DOI Direct Link
OncoGel (ReGel/paclitaxel)--clinical applications for a novel paclitaxel delivery system.
Cancer treatment regimens often include multiple anticancer agents...
3rd November, 2009
Protherics Salt Lake City, Inc., a BTG PLC Company, 2417 South 3850 West, Adv Drug Deliv Rev. 2009 Aug 10;61(10):785-94. Epub 2009 May 5.
DOI Direct Link
High prevalence of right-to-left shunt in patients with symptomatic great saphenous incompetence and varicose veins.
BACKGROUND: Varicose veins are common and increasingly are being treated...
20th October, 2009
BTG International Ltd in London, Lake Washington Vascular, Conshohocken, J Vasc Surg. 2009 Oct 16.
DOI Direct Link
BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache.
BACKGROUND AND PURPOSE: Prostanoid EP(4) receptor antagonists may have...
15th July, 2009
BTG International Ltd., 10 Fleet Place, Limeburner Lane, London, UK. Br J Pharmacol. 2009 Jan;156(2):316-27. Epub 2009 Jan 19.
DOI Direct Link

Press Releases on BTG:

BioPortfolio Logo
Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008 3rd November, 2009 Onyx Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the third quarter 2009. Global Nexavar net sales as reported by
Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications 26th October, 2009 Reportlinker
NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Immunotherapies and Vaccines for Nontraditional
Onyx Pharmaceuticals Initiates Phase 1 Study of ONX 0801 in Advanced Solid Tumors 28th September, 2009 Onyx Pharmaceuticals, Inc.
EMERYVILLE, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has begun enrolling patients in a Phase 1 study of ONX 0801, a novel alpha
Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 10th August, 2009 Savient Pharmaceuticals, Inc.
-- Raised $31.0 million from a registered direct offering that yielded $29.0 million in cash, net of $2.0 million of offering costs -- Elected Ginger D. Constantine, M.D. to the
SENEXIS APPOINTS CHRIS MOYSES AS CHAIRMAN AND DAVID SCOPES AS CHIEF 1st November, 2004 Senexis
SENEXIS APPOINTS CHRIS MOYSES AS CHAIRMAN AND DAVID SCOPES AS CHIEF SCIENTIFIC OFFICER Cambridge, UK, November 2004.  Senexis Limited announced today the appointment of

BioNews Results for BTG:

BTG revenues gain from Protherics buy
Pharma Times:  Nov 10 2009 11:45AM Matching: btg
Revenues rise at pharmaceuticals company BTG
Manufacturing Digital:  Nov 6 2009 10:53PM Matching: btg
Appointments update
Pharmafocus:  Nov 6 2009 9:56AM Matching: btg
Appointments update
Pharmafocus:  Nov 6 2009 9:56AM Matching: btg
Generation of therapeutic microfoam
PharmCast:  Nov 6 2009 5:24AM Matching: btg
Promote your company here: BioNewsCast - Press Release Distribution

View more BTG news.

BTG Clinical Trials:

Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Endovenous Microfoam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence

BTG Patents:

US Patent No.Title
6942165 Generation of therapeutic microfoam
7078028 Anti-neoplastic viral agents
7083924 Diagnostic method for the identification of foetal DNA in a material sample
7109705 Method of and apparatus for nuclear quadrupole resonance testing a sample
7116222 Combination magnetic tag

View more BTG patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 219 times since April 2007, the link to the organisation's website has been followed 34 times

Search for more companies in West Conshohocken

Search for more companies in Pennsylvania



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for BTG

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.